Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Edwards Lifesciences Corporation Common Stock (EW) vs Toast Inc. Class A Common Stock (TOST) Price & Performance

Edwards Lifesciences Corporation Common StockTrade
Toast Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Edwards Lifesciences Corporation Common Stock vs Toast Inc. Class A Common Stock — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $87.08 (market cap $49.15B), while Toast Inc. Class A Common Stock trades at $29.53 (market cap $17.85B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 2.8× Toast Inc. Class A Common Stock's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Toast Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.

EWTOST
Market Cap
$49.15B$17.85B
Volume
3,642,9696,311,718
Sector
HealthTechnology
52-Week High
$95.18$39.02
52-Week Low
$72.65$22.33
Enterprise Value
$45.60B$16.10B
Typical Hold Time
—0 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences (EW) trades at $85.27, down 1.3% with bearish technical signals. The company maintains strong fundamentals with 77.84% gross margins and recent FDA approval for the AUTUS pediatric valve. Despite a high P/E of 50.76, analysts project 20% upside to the $102.44 consensus target. Recent earnings show mixed results with Q1 and Q2 beats but a Q4 miss.

EW faces valuation concerns with declining net income margins from 17.69% to 15.43% year-over-year. Technical resistance at $86-89 and negative cash flow trends present near-term challenges. However, institutional accumulation and zero sell ratings suggest long-term confidence in structural heart growth platforms.

Toast Inc. Class A Common Stock

Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.

The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EW

No sentiment data available yet.

TOST
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.

Read more on EW →

About Toast Inc. Class A Common Stock

Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.

Read more on TOST →